Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Ferring

Status: Completed

Conditions: Advanced Hormone Sensitive Prostate Cancer

Treatments: Drug: degarelix

Study type: Observational

Funder types: Industry

Identifiers

NCT02229253

000171

Details and patient eligibility

About

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Enrollment: 112 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion criteria

• Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
• Planned intermittent or short-term (< 12 months) degarelix treatment
• Planned addition of, or switch to another form of androgen deprivation therapy during the study

Trial design

112 participants in 1 patient group

Degarelix

Description:

Treatment according to standard clinical practice.

Treatment:

Drug: degarelix